Gonal-F

Gonal‑F contains the active ingredient follitropin alfa, a recombinant follicle‑stimulating hormone supplied as a solution for subcutaneous injection. It is a prescription medication marketed in the European Union and is used in fertility treatment protocols. The product is supplied in a vial or pen, with strength varying by formulation, and belongs to the gonadotropin class. It is indicated for women with specific reproductive endocrine disorders and is administered under medical supervision.

Gonal‑F is prescribed for several fertility‑related conditions where stimulation of ovarian follicle development is required.

- Anovulatory infertility, such as in polycystic ovary syndrome, to induce ovulation. - Controlled ovarian stimulation in assisted reproductive technology (ART) procedures, including in vitro fertilisation. - Treatment of hypogonadotropic hypogonadism to restore normal gonadal function. - Preparation of the endometrium for embryo transfer in selected protocols. - Adjunct therapy in donor‑egg cycles to optimise follicular response.

The safety profile of Gonal‑F includes a range of observed adverse reactions, which are generally classified by frequency.

Common: - Injection‑site reactions such as redness, swelling, or mild pain. - Headache or mild dizziness. - Nausea, abdominal discomfort, or bloating. - Mild ovarian enlargement with multiple follicular cysts.

Serious: - Ovarian hyperstimulation syndrome (OHSS), which can be moderate to severe. - Multiple pregnancy (twins or higher order). - Thromboembolic events, including deep‑vein thrombosis or pulmonary embolism.

Before initiating Gonal‑F therapy, clinicians should evaluate patient history and monitor specific parameters to minimise risks.

- Confirm diagnosis of infertility and rule out contraindications such as ovarian cysts or malignancy. - Perform baseline ultrasound and hormone assessments to guide dosing. - Monitor follicular growth regularly to detect excessive response. - Adjust dose or discontinue if signs of ovarian hyperstimulation appear. - Counsel patients on the increased likelihood of multiple gestations. - Advise against use in uncontrolled thyroid disease or uncontrolled diabetes. - Ensure pregnancy testing before starting treatment.

Gonal‑F may interact with other medications or substances that affect ovarian response or coagulation pathways.

Avoid: - Concurrent use of other gonadotropins or high‑dose estrogen preparations without specialist guidance. - Medications that significantly increase the risk of thrombosis, such as hormonal contraceptives containing estrogen.

Use with caution: - Anticoagulant therapy (e.g., warfarin, direct oral anticoagulants) – monitor coagulation status. - Thyroid hormone replacement – adjust dose based on thyroid function tests. - Insulin or oral hypoglycaemic agents – monitor glucose control during treatment. - Aromatase inhibitors – may alter estrogen feedback and require dose adjustment.